ArticleCancers2019
Taxol-Loaded MSC-Derived Exosomes Provide a Therapeutic Vehicle to Target Metastatic Breast Cancer and Other Carcinoma Cells.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 234 citations in OpenAlex.
- Exosome-Based Drug Delivery Systems in Colorectal Cancer: Current Evidence and Future Perspectives.The AAPS journal · 2026Review
- Mesenchymal stromal/stem cells in tumour initiation, progression and therapy.Nature reviews. Cancer · 2026Review
- Potential Role of Exosomes in the Pathogenesis, Diagnosis, and Treatment of Ovarian Cancer.Cancers · 2026Review
- Mesenchymal stem cell-derived extracellular vesicle therapy in breast cancer: A systematic review and meta-analysis ofMolecular therapy. Oncology · 2026Review
- Exosomal nanocarriers for targeted drug delivery in cancer therapy.Discover oncology · 2026Review
- Transforming Cancer Care with Oncosomes: Insight into Biogenesis, Functional Role, and Therapeutic Potential.Pharmaceutics · 2026Review
- Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Digestive System Tumors: Modulating the Chronic Inflammatory Microenvironment.International journal of nanomedicine · 2026Review
- Exploring the therapeutic potential of human umbilical cord mesenchymal stem cells derived extracellular vesicles in cancer immunotherapy.Discover oncology · 2025Review
- Bacterial extracellular vesicles in osteoarthritis: a new bridge of the gut-joint axis.Gut microbes · 2025Review
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Exosomal transfer of miR-124 from engineered NK-92 cells inhibits breast cancer cell migration and induces apoptosis.Medical oncology (Northwood, London, England) · 2025Article
- Pre-formation loading of extracellular vesicles with exogenous molecules using photoporation.Journal of nanobiotechnology · 2025Article
- Engineered Extracellular Vesicles for Targeted Paclitaxel Delivery in Cancer Therapy: Advances, Challenges, and Prospects.Cellular and molecular bioengineering · 2025Review
- Extracellular vesicles as missiles for enhanced anti-tumor efficacy of oncolytic viruses: from disseminating oncolysis and anti-tumor immunity to targeted delivery.Cell communication and signaling : CCS · 2025Review
- Exosome-based approaches in cancer along with unlocking new insights into regeneration of cancer-prone tissues.Regenerative therapy · 2025Review
- Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders.Medical oncology (Northwood, London, England) · 2025Review
- Progress of mesenchymal stem cell-derived exosomes in targeted delivery of antitumor drugs.Cancer cell international · 2025Review
- Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025Review
- Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer.Pharmaceutics · 2025Review
- Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer.International journal of nanomedicine · 2025Review
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
MSC-derived exosomes display, among others, an efficient biocompatibility and a reduced intrinsic immunogenicity, representing a valuable vehicle for drug delivery in a tumor-therapeutic approach. Following treatment of several human mesenchymal stroma/stem-like cell (MSC) populations with sub-lethal concentrations of taxol for 24 h, exosomes were isolated and applied to different human cancer populations including A549 lung cancer, SK-OV-3 ovarian cancer, and MDA-hyb1 breast cancer cells. While MSC control exosomes revealed little if any growth inhibition on the tumor cells, exposure to taxol-loaded MSC-derived exosomes was associated with 80-90% cytotoxicity. A similar application of taxol-loaded exosomes from HuVEC displayed much fewer effects. Quantification by LC-MS/MS analysis demonstrated a 7.6-fold reduced taxol concentration in MSC exosomes when compared to equivalent cytotoxic in vitro effects achieved with taxol substances, indicating a specific and more efficient tumor-targeting property. Consequently, MSC-derived taxol exosomes were tested in vivo. Highly metastatic MDA-hyb1 breast tumors were induced in NODscid mice, and systemic intravenous application of MSC-derived taxol exosomes revealed a more than 60% reduction of subcutaneous primary tumors. Moreover, the amount of distant organ metastases observed at least in lung, liver, spleen, and kidney was reduced by 50% with MSC taxol exosomes, similar to the effects observed with taxol, although the concentration of taxol in exosomes was about 1000-fold reduced. Together, these findings in different cancer cell populations and in vivo provide promising future perspectives for drug-loaded MSC-derived exosomes in efficiently targeting primary tumors and metastases by reducing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.